Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.49 |
| ▸ | HTR3B | O95264 | 3/20 | 0.49 |
| ▸ | HTR3A | P46098 | 3/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18176142 | 0.88 | PDE10A (0.49) | HRH4MAPK1CCNT1PDE10A | |
| SCHEMBL22549300 | 0.88 | HRH4 (0.58) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL606294 | 0.77 | HRH4 (0.79) | HRH4 | |
| SCHEMBL18176131 | 0.76 | HSD11B1 (0.55) | HRH4HTR6CCNT1 | |
| SCHEMBL13490012 | 0.75 | HTR3A (0.62) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL25893531 | 0.75 | HSD11B1 (0.53) | HRH4HTR6CCNT1 | |
| SCHEMBL15830279 | 0.74 | PDE10A (0.58) | MAPK1CCNT1PDE10A | |
| SCHEMBL25893652 | 0.74 | HRH3 (0.47) | HRH4HTR6 | |
| SCHEMBL1588482 | 0.73 | HRH4 (0.79) | HRH4EML4ALK | |
| Acetic Acid SCHEMBL604873 | 0.72 | HRH4 (0.69) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-05-12 | — | — | US | disclosed |
| US-20200377487-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-12-03 | — | — | US | disclosed |
| US-20190241546-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-08-08 | — | — | US | disclosed |
| US-10081622-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-09-25 | — | — | US | disclosed |
| US-20170158677-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-08 | — | — | US | disclosed |
| US-9616059-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-04-11 | — | — | US | disclosed |
| EP-2176231-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-10-19 | — | — | EP | disclosed |
| US-20160095856-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-07 | — | — | US | disclosed |
| US-9255087-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-02-09 | — | — | US | disclosed |
| US-9102662-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-11 | — | — | US | disclosed |
| US-20150065520-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-05 | — | — | US | disclosed |
| US-20150057291-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20150057292-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20140228351-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-14 | — | — | US | disclosed |
| US-8673893-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-03-18 | — | — | US | disclosed |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| US-8299057-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-30 | — | — | US | disclosed |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-18 | — | — | US | disclosed |
| EP-2176231-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009013126-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081622-B2 | Substituted indazole derivatives active as kinase inhibitors | MAP3K19, ABL1, MAP3K20 | HTR3E 3859/4885HTR3B 3811/4885HTR3A 3902/4885 |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | HTR3E 3362/4885HTR3B 3512/4885HTR3A 3522/4885 |
| US-20160095856-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | HTR3E 3859/4885HTR3B 3811/4885HTR3A 3902/4885 |
| US-20200377487-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | HTR3E 3859/4885HTR3B 3811/4885HTR3A 3902/4885 |
| US-20190241546-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | HTR3E 3859/4885HTR3B 3811/4885HTR3A 3902/4885 |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | HTR3E 3362/4885HTR3B 3512/4885HTR3A 3522/4885 |
| US-20150065520-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | HTR3E 3859/4885HTR3B 3811/4885HTR3A 3902/4885 |
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | HTR3E 3859/4885HTR3B 3811/4885HTR3A 3902/4885 |
| US-20150057292-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | HTR3E 3859/4885HTR3B 3811/4885HTR3A 3902/4885 |
| US-20140228351-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | HTR3E 3859/4885HTR3B 3811/4885HTR3A 3902/4885 |
| US-20150057291-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | HTR3E 3859/4885HTR3B 3811/4885HTR3A 3902/4885 |
| US-20170158677-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | HTR3E 3859/4885HTR3B 3811/4885HTR3A 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.